Literature DB >> 18720306

Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment.

Angela Tincani1, Chiara Bazzani, Stefania Zingarelli, Andrea Lojacono.   

Abstract

The antiphospholipid syndrome (APS) in pregnancy is associated with repeated miscarriages and fetal loss. Other complications of pregnancy such as preeclampsia and placental insufficiency are also frequently reported during pregnancy in APS. The pathogenesis of pregnancy failures in APS is related to both the thrombophilic effect of antiphospholipid antibodies and also to different mechanisms including a direct effect of antibodies on trophoblast differentiation and invasion. Although optimal pharmacologic treatment is essential to achieve a successful outcome in APS pregnancy, the standard APS pharmacologic treatment alone may not be sufficient. A good obstetric outcome is the result of careful obstetric monitoring, proper delivery timing, and skillful neonatal care. A multidisciplinary team (obstetricians, rheumatologists, and neonatologists) and the progress in neonatal intensive care are as important as drugs in achieving a good obstetric outcome and to reduce the possible consequences of premature delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720306     DOI: 10.1055/s-0028-1082270

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  16 in total

1.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

2.  Pregnancy and catastrophic antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Jose Sanin-Blair; Claudio Galarza-Maldonado
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Top 10 clinical research developments in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 4.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

Authors:  A M Lynch; J E Salmon
Journal:  Placenta       Date:  2010-04-27       Impact factor: 3.481

Review 5.  Neonatal effects of maternal antiphospholipid syndrome.

Authors:  Angela Tincani; Chiara Biasini Rebaioli; Laura Andreoli; Andrea Lojacono; Mario Motta
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

6.  Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

Authors:  Hannah L Rose; Wai Khoon Ho
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

Review 7.  Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome.

Authors:  Guillermina Girardi
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

Review 8.  Pregnancy and autoimmune connective tissue diseases.

Authors:  Wendy Marder; Emily A Littlejohn; Emily C Somers
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-06-25       Impact factor: 4.098

9.  Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.

Authors:  Jane E Salmon; Cara Heuser; Michael Triebwasser; M Kathryn Liszewski; David Kavanagh; Lubka Roumenina; D Ware Branch; Tim Goodship; Veronique Fremeaux-Bacchi; John P Atkinson
Journal:  PLoS Med       Date:  2011-03-22       Impact factor: 11.069

10.  A role for uric acid and the Nalp3 inflammasome in antiphospholipid antibody-induced IL-1β production by human first trimester trophoblast.

Authors:  Melissa J Mulla; Jane E Salmon; Larry W Chamley; Jan J Brosens; Crina M Boeras; Paula B Kavathas; Vikki M Abrahams
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.